{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:48:42Z","timestamp":1792064922153,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognosis of patients with pancreatic cancer (PC) is generally poor. However, favorable outcomes have recently been reported in selected patients with metastatic PC who receive multidisciplinary treatment. Oligometastasis (OM) represents a limited metastatic state and may be associated with better prognosis than multiple metastases (MM). The clinical role of locoregional therapy (LT) for postoperative OM remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included all consecutive patients with pancreatic malignancies who underwent macroscopically curative resection between 2013 and 2018. Patients with postoperative recurrence were divided into OM and MM groups. Survival outcomes and treatment after recurrence were compared between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 150 patients were evaluated. Postoperative recurrence was classified as OM in 29 patients and MM in 71 patients. Among the patients with OM, 10 underwent LT. Overall survival and survival after recurrence were significantly longer in the OM group than in the MM group. Among patients with OM, those who underwent LT showed longer survival after recurrence than those who received chemotherapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with postoperative OM after pancreatic cancer surgery showed more favorable survival outcomes than those with MM. In carefully selected patients with postoperative OM, LT combined with chemotherapy was associated with longer survival after recurrence. However, because of the retrospective single-center design, small number of treated patients, and potential selection bias, LT should be regarded as a possible treatment option rather than an established therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16566-2","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:56:37Z","timestamp":1784552197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical benefit of locoregional therapy for oligometastasis after surgery for pancreatic cancer: a single center retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Koki","family":"Ichio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Einama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yonamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takazumi","family":"Tsunenari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiya","family":"Takao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"16566_CR1","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/WJG.V24.I43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846. https:\/\/doi.org\/10.3748\/WJG.V24.I43.4846.","journal-title":"World J Gastroenterol"},{"key":"16566_CR2","doi-asserted-by":"publisher","unstructured":"Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, et al. Updated trends in cancer in Japan: Incidence in 1985\u20132015 and mortality in 1958\u20132018-A sign of decrease in cancer incidence. J Epidemiol. 2021;31:426\u201350. https:\/\/doi.org\/10.1093\/JJCO\/HYT038\u00a0, https:\/\/doi.org\/10.1186\/S12885-022-10116-2.","DOI":"10.1093\/JJCO\/HYT038"},{"key":"16566_CR3","doi-asserted-by":"publisher","unstructured":"Kobayashi K, Einama T, Takihata Y, Yonamine N, Fujinuma I, Tsunenari T, et al. Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study. BMC Cancer. 2022;22.\u00a0https:\/\/doi.org\/10.1186\/S12885-022-10116-2.","DOI":"10.1186\/S12885-022-10116-2"},{"key":"16566_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.6004\/JNCCN.2017.0138","volume":"15","author":"T Golan","year":"1993","unstructured":"Golan T, Sella T, Margalit O, Amit U, Halpern N, Aderka D, et al. Short- and long-term survival in metastatic pancreatic adenocarcinoma, 1993-2013. J Natl Compr Canc Netw. 1993;15:1022\u20137. https:\/\/doi.org\/10.6004\/JNCCN.2017.0138.","journal-title":"J Natl Compr Canc Netw"},{"key":"16566_CR5","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.18632\/aging.202570","volume":"13","author":"T Lianyuan","year":"2021","unstructured":"Lianyuan T, Deyu L, Haibo Y, Yadong D, Guanjing T. Clinical features and prognostic factors of elderly patients with metastatic pancreatic cancer: a population-based study. Aging (Albany NY). 2021;13:7133\u201346. https:\/\/doi.org\/10.18632\/aging.202570.","journal-title":"Aging (Albany NY)"},{"key":"16566_CR6","doi-asserted-by":"publisher","unstructured":"Einama T, Takihata Y, Aosasa S, Konno F, Kobayashi K, Yonamine N, et al. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Cancers (Basel). 2023;15.\u00a0https:\/\/doi.org\/10.3390\/CANCERS15041101.","DOI":"10.3390\/CANCERS15041101"},{"key":"16566_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8.","journal-title":"J Clin Oncol"},{"key":"16566_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/JHBP.1184","volume":"00","author":"T Takeda","year":"2022","unstructured":"Takeda T, Sasaki T, Okamoto T, Kasuga A, Matsuyama M, Ozaka M, et al. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat Sci. 2022;00:1\u201311. https:\/\/doi.org\/10.1002\/JHBP.1184.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"16566_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/J.PAN.2019.05.466","volume":"19","author":"T Sakaguchi","year":"2019","unstructured":"Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: a review of current literature. Pancreatology. 2019;19:672\u201380. https:\/\/doi.org\/10.1016\/J.PAN.2019.05.466.","journal-title":"Pancreatology"},{"key":"16566_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-019-6448-9","author":"AI Damanakis","year":"2019","unstructured":"Damanakis AI, Ostertag L, Waldschmidt D, K\u00fctting F, Quaas A, Plum P, et al. Proposal for a definition of \u201coligometastatic disease in pancreatic cancer.\u201d BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/S12885-019-6448-9.","journal-title":"BMC Cancer"},{"key":"16566_CR11","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.21873\/ANTICANRES.15189","volume":"41","author":"M Yamanaka","year":"2021","unstructured":"Yamanaka M, Hayashi M, Yamada S, Sonohara F, Takami H, Inokawa Y, et al. A possible definition of oligometastasis in pancreatic cancer and associated survival outcomes. Anticancer Res. 2021;41:3933\u201340. https:\/\/doi.org\/10.21873\/ANTICANRES.15189.","journal-title":"Anticancer Res"},{"key":"16566_CR12","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/J.SURG.2021.12.029","volume":"171","author":"A Hamad","year":"2022","unstructured":"Hamad A, Underhill J, Ansari A, Thayaparan V, Cloyd JM, Li Y, et al. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the National Cancer Database. Surgery. 2022;171:1464\u201370. https:\/\/doi.org\/10.1016\/J.SURG.2021.12.029.","journal-title":"Surgery"},{"key":"16566_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.6092\/1590-8577\/739","volume":"13","author":"Y Kitasato","year":"2012","unstructured":"Kitasato Y, Nakayama M, Akasu G, Yoshitomi M, Mikagi K, Maruyama Y, et al. Metastatic Pulmonary Adenocarcinoma 13 Years After Curative Resection for Pancreatic Cancer: Report of a Case and Review of Japanese Literature. JOP. 2012;13:296\u2013300. https:\/\/doi.org\/10.6092\/1590-8577\/739.","journal-title":"JOP"},{"key":"16566_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/J.SURONC.2020.08.005","volume":"35","author":"C Schwarz","year":"2020","unstructured":"Schwarz C, Fitschek F, Primavesi F, St\u00e4ttner S, Margonis GA, Weiss MA, et al. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol. 2020;35:169\u201373. https:\/\/doi.org\/10.1016\/J.SURONC.2020.08.005.","journal-title":"Surg Oncol"},{"key":"16566_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.hpb.2018.12.002","volume":"21","author":"VP Groot","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, van Oosten AF, et al. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford). 2019;21:998\u20131008. https:\/\/doi.org\/10.1016\/j.hpb.2018.12.002.","journal-title":"HPB (Oxford)"},{"key":"16566_CR16","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th edition. John Wiley & Sons; 2017.","edition":"8th edition"},{"key":"16566_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9.","journal-title":"Lancet"},{"key":"16566_CR18","doi-asserted-by":"publisher","unstructured":"Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, et al. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Cancers (Basel). 2019;11.\u00a0https:\/\/doi.org\/10.3390\/CANCERS11081095.","DOI":"10.3390\/CANCERS11081095"},{"key":"16566_CR19","doi-asserted-by":"publisher","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, et al. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers (Basel). 2021;13.\u00a0https:\/\/doi.org\/10.3390\/cancers13071608.","DOI":"10.3390\/cancers13071608"},{"key":"16566_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/AGS3.12655","volume":"7","author":"S Yasuda","year":"2021","unstructured":"Yasuda S, Nagai M, Terai T, Kohara Y, Sho M. Essential updates 2021\/2022: surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2021;7:358. https:\/\/doi.org\/10.1002\/AGS3.12655.","journal-title":"Ann Gastroenterol Surg"},{"key":"16566_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102067","volume":"8","author":"CS Leonhardt","year":"2023","unstructured":"Leonhardt CS, Stamm T, Hank T, Prager G, Strobel O. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open. 2023;8:102067. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102067.","journal-title":"ESMO Open"},{"key":"16566_CR22","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"key":"16566_CR23","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMOA1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMOA1304369.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16566-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:57:32Z","timestamp":1792061852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16566-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16566"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16566-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of the National Defense Medical College, Tokorozawa, Japan (No. 4610). The requirement for written informed consent was waived due to the retrospective nature of the study. All methods were carried out following relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1231"}}